Skip to main content
. 2018 Feb 6;9(17):13623–13636. doi: 10.18632/oncotarget.24426

Figure 6. 4D5 gene transfer and 4D5 protein administration in BALB/c mice.

Figure 6

(A) Plasma 4D5 concentrations following a single intramuscular (i.m.) electrotransfer of pCAG-4D5-HCLC (heavy chain – light chain order) and pCAG-4D5-LCHC (light chain – high chain order). (B) Impact of repeated electrotransfer of 60 µg pCAG-4D5 on plasma 4D5 concentrations. The arrow indicates the timing of the second pCAG-4D5 dose. (C) Plasma 4D5 concentrations resulting from i.m. electrotransfer of equimolar amounts of pCAG-4D5 and muscle-specific p∆USE-4D5. ***P < 0.001, ****P < 0.0001. (D) Plasma 4D5 pharmacokinetics of a single intravenous (i.v.) injection of 5 µg purified 4D5. The first plasma sample post injection was collected after one hour.